Barriers to care in patients with diabetes and poor glycemic control-A cross-sectional survey

PLoS One. 2017 May 1;12(5):e0176135. doi: 10.1371/journal.pone.0176135. eCollection 2017.

Abstract

Aims: To determine and quantify the prevalence of patient, provider and system level barriers to achieving diabetes care goals; and to examine whether barriers were different for people with poor glycemic control (HbA1c ≥ 10%; 86 mmol/mol) compared to fair glycemic control (7 to <8%; 53-64 mmol/mol).

Methods: We administered a survey by telephone to community-dwelling patients with diabetes, to examine patient-reported barriers and facilitators to care. We compared responses in individuals with HbA1c ≥ 10% (86 mmol/mol) against those with HbA1c between 7-8% (53-64 mmol/mol). We examined associations between HbA1c group and barriers to care, adjusting for sociodemographic factors and diabetes duration.

Results: The survey included 805 people with HbA1c ≥ 10% (86 mmol/mol), and 405 people with HbA1c 7-8% (53-64 mmol/mol). Participants with HbA1c ≥ 10% (86 mmol/mol) reported good access to care, however 20% of participants with HbA1c ≥ 10% (86 mmol/mol) felt that their care was not well-coordinated and 9.6% reported having an unmet health care need. In adjusted analysis, patients with HbA1c ≥10% (86 mmol/mol) were more likely to report lack of confidence and inadequate social support, compared to patients with HbA1c 7-8% (53-64 mmol/mol). They were also significantly more likely not to have drug insurance nor to have received recommended treatments because of cost.

Conclusions: These results reinforce the importance of an individualized, yet multi-faceted approach. Specific attention to financial barriers seems warranted. These findings can inform the development of programs and initiatives to overcome barriers to care, and improve diabetes care and outcomes.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alberta / epidemiology
  • Biomarkers / blood
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / economics
  • Diabetes Mellitus, Type 2 / epidemiology*
  • Female
  • Glycated Hemoglobin / metabolism
  • Health Services Accessibility*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insurance, Pharmaceutical Services
  • Interviews as Topic
  • Male
  • Middle Aged
  • Self Care
  • Self Report
  • Social Support

Substances

  • Biomarkers
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • hemoglobin A1c protein, human

Grants and funding

This study was funded by a Canadian Diabetes Association operating grant and by an Alberta Innovates - Health Solutions (AI-HS) team grant to the Interdisciplinary Chronic Disease Collaboration (ICDC). The funders were not involved in study design, data collection and analysis, decision to publish, or preparation of the manuscript.